GLP-1 drugs , or glucagon-like peptide-1 receptor agonists , represent a truly shift in how we approach high blood sugar. These new therapies function to mimicking the body’s inherent GLP-1 substance , which promotes glucose regulation and diminishes glucagon secretion . Beyond blood sugar control ,